Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (21671)	2/23/2000 1:50:00 PM
From: John Tinsley	Read Replies (1) \| Respond to of 25711

It's pulled back from 3 during lunch time. I just picked up a little in hopes of an end of day run (counting on the pull back to be MM games).

To: Joe Copia who wrote (21671)	2/23/2000 2:19:00 PM
From: OFW	Respond to of 25711

IMDS News Just Out . . . FORT LAUDERDALE, Fla., Feb. 23 /PRNewswire/ -- Imaging Diagnostic Systems Inc., (OTC Bulletin Board: IMDS) announced today that it was granted approval on February 8 to conduct clinical studies for the use of Diagnostic Breast Imaging (CTLM)(TM) with Indocyanine Green contrast agent (ICG). The studies, which are limited to 50 subjects, will begin once the Company has obtained approval from the Institutional Review Boards (IRB) of the medical institutions that have been selected by Imaging Diagnostic Systems. The goal of the study is to investigate the use of fluorescent compounds, such as ICG, to determine if it increases the imaging sensitivity of the CTLM(TM). The FDA approved contrast agent, ICG, will be used in this study to enhance the presence of a suspicious lesion. "In these preliminary studies, we hope to demonstrate the potential of contrast agents together with the CTLM(TM) device to more accurately predict the outcome of a biopsy and use this as an advantage in diagnosing breast abnormalities," said Richard Grable, CEO. Imaging Diagnostic Systems has developed the world's first patented laser- based breast imaging device, known as the CTLM(TM), that utilizes state-of- the-art laser technology and patented computed algorithms that create contiguous cross sectional slice images of the breast without the use of breast compression or x-rays. SOURCE Imaging Diagnostic Systems, Inc. -0- 02/23/2000 /CONTACT: Deborah O'Brien of Imaging Diagnostic Systems, Inc., 954-581-9800/ /Web site: imds.com /